235 related articles for article (PubMed ID: 36980775)
1. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.
Martin M; Ballal S; Yadav MP; Bal C; Van Rymenant Y; De Loose J; Verhulst E; De Meester I; Van Der Veken P; Roesch F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980775
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F
Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886
[TBL] [Abstract][Full Text] [Related]
3. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of [
Yadav MP; Ballal S; Martin M; Roesch F; Satapathy S; Moon ES; Tripathi M; Gogia A; Bal C
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):805-819. PubMed ID: 37932560
[TBL] [Abstract][Full Text] [Related]
5. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
6. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
7. [
Ballal S; Yadav MP; Raju S; Roesch F; Martin M; Tripathi M; Bal C
Nucl Med Mol Imaging; 2024 Feb; 58(1):32-34. PubMed ID: 38261876
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [
Bao G; Zhou H; Zou S; Chen L; Zhang B; Wang Z; Moon ES; Zhao J; Roesch F; Zhu X
Mol Pharm; 2023 May; 20(5):2443-2451. PubMed ID: 37067162
[TBL] [Abstract][Full Text] [Related]
9. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
10. Targeting CXCR4/CXCL12 axis via [
Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38587644
[TBL] [Abstract][Full Text] [Related]
11. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
12. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
15. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
[TBL] [Abstract][Full Text] [Related]
17. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study.
Ballal S; Yadav MP; Moon ES; Roesch F; Kumari S; Agarwal S; Tripathi M; Sahoo RK; Mangu BS; Tupalli A; Bal C
Thyroid; 2022 Jan; 32(1):65-77. PubMed ID: 34641705
[No Abstract] [Full Text] [Related]
18. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.
Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G
Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
